Cytokinetics (CYTK) Competitors $34.54 +1.41 (+4.26%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$34.40 -0.14 (-0.39%) As of 06/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Intra-Cellular Therapies (NASDAQ:ITCI) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Do analysts prefer ITCI or CYTK? Intra-Cellular Therapies presently has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Cytokinetics has a consensus price target of $70.92, suggesting a potential upside of 105.34%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 Does the media favor ITCI or CYTK? In the previous week, Cytokinetics had 19 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 19 mentions for Cytokinetics and 0 mentions for Intra-Cellular Therapies. Cytokinetics' average media sentiment score of 0.51 beat Intra-Cellular Therapies' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Cytokinetics Positive Which has stronger valuation & earnings, ITCI or CYTK? Intra-Cellular Therapies has higher revenue and earnings than Cytokinetics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Cytokinetics$19.22M214.64-$526.24M-$5.29-6.53 Is ITCI or CYTK more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Cytokinetics -17,906.25%N/A -50.21% Which has more volatility and risk, ITCI or CYTK? Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Does the MarketBeat Community favor ITCI or CYTK? Cytokinetics received 309 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.83% of users gave Cytokinetics an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% CytokineticsOutperform Votes83179.83% Underperform Votes21020.17% Do insiders & institutionals believe in ITCI or CYTK? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 2.7% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCytokinetics beats Intra-Cellular Therapies on 12 of the 19 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.13B$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-6.428.7927.2120.17Price / Sales214.64263.51414.99161.94Price / CashN/A65.8538.2534.64Price / Book-8.776.677.124.72Net Income-$526.24M$143.49M$3.23B$247.80M7 Day Performance6.57%5.15%3.80%2.76%1 Month Performance8.99%15.43%13.40%9.71%1 Year Performance-35.18%6.02%32.04%14.51% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.0811 of 5 stars$34.54+4.3%$70.92+105.3%-36.2%$4.13B$19.22M-6.42250Trending NewsAnalyst ForecastAnalyst RevisionITCIIntra-Cellular Therapies0.9031 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.285 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics3.0215 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Analyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.2409 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.2894 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4393 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.2307 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.1584 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.9085 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640Positive NewsGap UpHigh Trading VolumeROIVRoivant Sciences2.3799 of 5 stars$11.17+1.6%$17.50+56.7%+7.5%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTK Stock Free CYTK Stock Alerts